Menu
Back to User profile » Dr Claus Vogelmeier
Papers published by Dr Claus Vogelmeier:
Risk of Pneumonia in Patients with COPD Initiating Fixed Dose Inhaled Corticosteroid (ICS) / Long-Acting Bronchodilator (LABD) Formulations Containing Extrafine Beclometasone Dipropionate versus Patients Initiating LABD Without ICS
Price D, Henley W, Cançado JED, Fabbri LM, Kerstjens HA, Papi A, Roche N, Şen E, Singh D, Vogelmeier CF, Nudo E, Carter V, Skinner D, Vella R, Soriano JB, Kots M, Georges G
Pragmatic and Observational Research 2024, 15:1-16
Published Date: 20 January 2024
Characteristics of Current Smokers versus Former Smokers with COPD and Their Associations with Smoking Cessation Within 4.5 Years: Results from COSYCONET
Alter P, Stoleriu C, Kahnert K, Henke MO, Bals R, Trudzinski FC, Watz H, Speicher T, Söhler S, Welte T, Rabe KF, Wouters EFM, Vogelmeier CF, Jörres RA
International Journal of Chronic Obstructive Pulmonary Disease 2023, 18:2911-2923
Published Date: 6 December 2023
Real-World Treatment of Patients Newly Diagnosed with Chronic Obstructive Pulmonary Disease: A Retrospective German Claims Data Analysis
Buhl R, Wilke T, Picker N, Schmidt O, Hechtner M, Kondla A, Maywald U, Vogelmeier CF
International Journal of Chronic Obstructive Pulmonary Disease 2022, 17:2355-2367
Published Date: 22 September 2022
Interclass Difference in Pneumonia Risk in COPD Patients Initiating Fixed Dose Inhaled Treatment Containing Extrafine Particle Beclometasone versus Fine Particle Fluticasone [Corrigendum]
Price DB, Henley W, Cançado JED, Fabbri LM, Kerstjens HA, Papi A, Roche N, Şen E, Singh D, Vogelmeier CF, Barille S, Nudo E, Carter V, Skinner D, Vella R, Georges G
International Journal of Chronic Obstructive Pulmonary Disease 2022, 17:489-490
Published Date: 7 March 2022
Interclass Difference in Pneumonia Risk in COPD Patients Initiating Fixed Dose Inhaled Treatment Containing Extrafine Particle Beclometasone versus Fine Particle Fluticasone
Price DB, Henley W, Cançado JED, Fabbri LM, Kerstjens HA, Papi A, Roche N, Şen E, Singh D, Vogelmeier CF, Barille S, Nudo E, Carter V, Skinner D, Vella R, Georges G
International Journal of Chronic Obstructive Pulmonary Disease 2022, 17:355-370
Published Date: 15 February 2022
Lower Prevalence of Osteoporosis in Patients with COPD Taking Anti-Inflammatory Compounds for the Treatment of Diabetes: Results from COSYCONET
Kahnert K, Jörres RA, Lucke T, Trudzinski FC, Mertsch P, Bickert C, Ficker JH, Behr J, Bals R, Watz H, Welte T, Vogelmeier CF, Alter P
International Journal of Chronic Obstructive Pulmonary Disease 2021, 16:3189-3199
Published Date: 24 November 2021
Impact of Lung Function and Exacerbations on Health-Related Quality of Life in COPD Patients Within One Year: Real-World Analysis Based on Claims Data
Stöber A, Lutter JI, Schwarzkopf L, Kirsch F, Schramm A, Vogelmeier CF, Leidl R
International Journal of Chronic Obstructive Pulmonary Disease 2021, 16:2637-2651
Published Date: 21 September 2021
Treatment of COPD Groups GOLD A and B with Inhaled Corticosteroids in the COSYCONET Cohort – Determinants and Consequences
Lutter JI, Jörres RA, Trudzinski FC, Alter P, Kellerer C, Watz H, Welte T, Bals R, Kauffmann-Guerrero D, Behr J, Holle R, Vogelmeier CF, Kahnert K
International Journal of Chronic Obstructive Pulmonary Disease 2021, 16:987-998
Published Date: 14 April 2021